fda warning letters glp-1 compounders september 2025 news restricts non-approved compounded weight loss products From Crackdown to Collaboration: FDA

Negative control outcomes: A tool to detect bias in randomized trials

In vivo rodent models have explored the compound's influence on circadian clock gene expression in the suprachiasmatic nucleus, examining whether exogenous DSIP administration alters Per and Cry transcription rhythms

Anecdotal reports have suggested that the use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) might be associated with a rare cause of sudden blindness called non-arteritic anterior ischemic optic neuropathy (NAION)

66 There is a real need for treatments that can change the course of the disease

Metabolic Health : Assists in fat metabolism, potentially aiding in weight management and body composition